Salarius Pharmaceuticals, Inc.DCOYEarnings & Financial Report
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm developing targeted therapies for rare, high-unmet-need cancers including Ewing sarcoma and pediatric solid tumors. It advances novel small molecule candidates to improve outcomes for patients with limited existing treatment options.
DCOY Q1 FY2023 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.4M
Net Profit
$-5.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.23
Salarius Pharmaceuticals, Inc. Q1 FY2023 Financial Summary
Salarius Pharmaceuticals, Inc. reported revenue of $0 for Q1 FY2023, with a net profit of $-5.3M (up 12.6% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-5.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2023 |
Salarius Pharmaceuticals, Inc. Annual Revenue by Year
Salarius Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).
Salarius Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Salarius Pharmaceuticals, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $0 | — | $-5.3M | N/A |
| Q4 FY2022 | $0 | — | $-6.4M | N/A |
| Q3 FY2022 | $0 | — | $-14.4M | N/A |
| Q2 FY2022 | $0 | — | $-4.7M | N/A |
| Q1 FY2022 | $0 | — | $-6.1M | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Assets | $35.5M | $33.7M | $19.7M | $14.7M | $10.1M |
| Liabilities | $2.1M | $2.8M | $3.1M | $4.3M | $4.5M |
| Equity | $33.4M | $30.9M | $16.6M | $10.4M | $5.6M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-3.5M | $-3.6M | $-5.7M | $-4.7M | $-3.2M |